An explanation of what DMT is:
While ayahuasca, a hallucinogenic and often purgative tea brewed from leaves of a shrub that grows in South America, contains the psychoactive compound N, N-dimethyltryptamine (DMT), it also packs harmine and tetrahydoharmine, two compounds that form new neurons from stem cells in a petri dish, per IFL Science.
Ayahuasca is used in spiritual practices across different belief systems, and Healthline explains that the plant’s naturally occurring DMT—which can produce powerful hallucinations and visions—works in tandem with another compound that makes it more “bioavailable.” That means it’s absorbed better by the body, with less flushed out as waste afterward. Think about how calcium and vitamin D work together to increase absorption.
Don't worry, this will never get approved in the US
Stroke victims to be given psychedelic drug DMT in groundbreaking study
Psychedelic drug DMT could help stroke victims recover by rewiring their brains faster, according the first clinical trial of its kind. It is hoped the substance, also known as the ‘the spirit molecule’, could even be given to patients as soon as they’re in the ambulance, minimising the damage and maximising their recovery. Algernon Pharmaceuticals, who set out the plan for their study this week, say participants will be given a microdose, which won’t make them ‘trip’, but will still help the neurons in their brain make new connections. If the trial proves successful and gets regulatory approval, it could open up a whole new world of research for people with multiple sclerosis, Parkinson’s and many other conditions affecting the brain. Among the study’s global luminaries is Professor David Nutt, of Imperial College London’s Centre for Psychedelic Research, which has looked into potential for psilocybin (magic mushrooms) to treat depression. Algernon, based in Vancouver, Canada, are the world’s first company to try using DMT (dimethyltryptamine) for strokes, and if they get promising results, they hope to be fast-tracked by regulators in the US. CEO Christopher Moreau told Metro.co.uk: Since we’re dealing with stroke patients, we will be using the sub-hallucinogenic dose, which in pre-clinical studies has still shown to improve neuroplasticity. ‘It will help the brain heal even though patients aren’t having the psychedelic experience, and we really don’t want that if your patient has just had a stroke.’ DMT occurs in many plants and animals, but Algernon will produce theirs synthetically (Picture: Getty Images) Algernon have been buoyed by a study last year in which blood flow was blocked off for one half of the brain in rats. Rodents who were given DMT recovered motor-function and rebuilt brain cells more efficiently and had fewer lesions on the brain. ‘We’re going to take that information now and move very quickly to test it in humans,’ Mr Moreau said. He explained how there is still ‘very little available’ for stroke victims in the immediate aftermath and that DMT could help fill the void. Part of the problem is that two of the main types of stroke are very different and require different types of treatment. Christopher Moreau, CEO of Algernon Pharmaceuticals, based in Vancouver, Canada Christopher Moreau hopes the study could open a whole new field for people with other illnesses (Picture: Algernon Pharmaceuticals) Ischemic strokes occur due to a blood clot blocking a vessel in the brain and are often treated with blood thinner. But if you did this for someone suffering from a haemorrhagic stroke – caused by bleeding in or around the brain – you could kill them. For this reason patients have to wait for a CT scan, which could take hours, leaving more time for the brain to incur damage. Mr Moreau said: ‘The sooner you can start to treat post-injury the better. DMT may not benefit hemorrhagic, we don’t know, but we’re hoping it won’t cause them any problems because then we don’t have to wait for the CT scan, we can treat in the ambulance.
Read more: https://metro.co.uk/2021/02/04/stroke-victims-to-be-given-psychedelic-drug-dmt-in-groundbreaking-study-14023757/?ito=cbshare
Twitter: https://twitter.com/MetroUK | Facebook: https://www.facebook.com/MetroUK/
Psychedelic drug DMT could help stroke victims recover by rewiring their brains faster, according the first clinical trial of its kind. It is hoped the substance, also known as the ‘the spirit molecule’, could even be given to patients as soon as they’re in the ambulance, minimising the damage and maximising their recovery. Algernon Pharmaceuticals, who set out the plan for their study this week, say participants will be given a microdose, which won’t make them ‘trip’, but will still help the neurons in their brain make new connections. If the trial proves successful and gets regulatory approval, it could open up a whole new world of research for people with multiple sclerosis, Parkinson’s and many other conditions affecting the brain. Among the study’s global luminaries is Professor David Nutt, of Imperial College London’s Centre for Psychedelic Research, which has looked into potential for psilocybin (magic mushrooms) to treat depression. Algernon, based in Vancouver, Canada, are the world’s first company to try using DMT (dimethyltryptamine) for strokes, and if they get promising results, they hope to be fast-tracked by regulators in the US. CEO Christopher Moreau told Metro.co.uk: Since we’re dealing with stroke patients, we will be using the sub-hallucinogenic dose, which in pre-clinical studies has still shown to improve neuroplasticity. ‘It will help the brain heal even though patients aren’t having the psychedelic experience, and we really don’t want that if your patient has just had a stroke.’ DMT occurs in many plants and animals, but Algernon will produce theirs synthetically (Picture: Getty Images) Algernon have been buoyed by a study last year in which blood flow was blocked off for one half of the brain in rats. Rodents who were given DMT recovered motor-function and rebuilt brain cells more efficiently and had fewer lesions on the brain. ‘We’re going to take that information now and move very quickly to test it in humans,’ Mr Moreau said. He explained how there is still ‘very little available’ for stroke victims in the immediate aftermath and that DMT could help fill the void. Part of the problem is that two of the main types of stroke are very different and require different types of treatment. Christopher Moreau, CEO of Algernon Pharmaceuticals, based in Vancouver, Canada Christopher Moreau hopes the study could open a whole new field for people with other illnesses (Picture: Algernon Pharmaceuticals) Ischemic strokes occur due to a blood clot blocking a vessel in the brain and are often treated with blood thinner. But if you did this for someone suffering from a haemorrhagic stroke – caused by bleeding in or around the brain – you could kill them. For this reason patients have to wait for a CT scan, which could take hours, leaving more time for the brain to incur damage. Mr Moreau said: ‘The sooner you can start to treat post-injury the better. DMT may not benefit hemorrhagic, we don’t know, but we’re hoping it won’t cause them any problems because then we don’t have to wait for the CT scan, we can treat in the ambulance.
Read more: https://metro.co.uk/2021/02/04/stroke-victims-to-be-given-psychedelic-drug-dmt-in-groundbreaking-study-14023757/?ito=cbshare
Twitter: https://twitter.com/MetroUK | Facebook: https://www.facebook.com/MetroUK/
Psychedelic drug DMT could help stroke victims recover by rewiring their brains faster, according the first clinical trial of its kind. It is hoped the substance, also known as the ‘the spirit molecule’, could even be given to patients as soon as they’re in the ambulance, minimising the damage and maximising their recovery. Algernon Pharmaceuticals, who set out the plan for their study this week, say participants will be given a microdose, which won’t make them ‘trip’, but will still help the neurons in their brain make new connections. If the trial proves successful and gets regulatory approval, it could open up a whole new world of research for people with multiple sclerosis, Parkinson’s and many other conditions affecting the brain. Among the study’s global luminaries is Professor David Nutt, of Imperial College London’s Centre for Psychedelic Research, which has looked into potential for psilocybin (magic mushrooms) to treat depression. Algernon, based in Vancouver, Canada, are the world’s first company to try using DMT (dimethyltryptamine) for strokes, and if they get promising results, they hope to be fast-tracked by regulators in the US. CEO Christopher Moreau told Metro.co.uk: Since we’re dealing with stroke patients, we will be using the sub-hallucinogenic dose, which in pre-clinical studies has still shown to improve neuroplasticity. ‘It will help the brain heal even though patients aren’t having the psychedelic experience, and we really don’t want that if your patient has just had a stroke.’ DMT occurs in many plants and animals, but Algernon will produce theirs synthetically (Picture: Getty Images) Algernon have been buoyed by a study last year in which blood flow was blocked off for one half of the brain in rats. Rodents who were given DMT recovered motor-function and rebuilt brain cells more efficiently and had fewer lesions on the brain. ‘We’re going to take that information now and move very quickly to test it in humans,’ Mr Moreau said. He explained how there is still ‘very little available’ for stroke victims in the immediate aftermath and that DMT could help fill the void. Part of the problem is that two of the main types of stroke are very different and require different types of treatment. Christopher Moreau, CEO of Algernon Pharmaceuticals, based in Vancouver, Canada Christopher Moreau hopes the study could open a whole new field for people with other illnesses (Picture: Algernon Pharmaceuticals) Ischemic strokes occur due to a blood clot blocking a vessel in the brain and are often treated with blood thinner. But if you did this for someone suffering from a haemorrhagic stroke – caused by bleeding in or around the brain – you could kill them. For this reason patients have to wait for a CT scan, which could take hours, leaving more time for the brain to incur damage. Mr Moreau said: ‘The sooner you can start to treat post-injury the better. DMT may not benefit hemorrhagic, we don’t know, but we’re hoping it won’t cause them any problems because then we don’t have to wait for the CT scan, we can treat in the ambulance.
Read more: https://metro.co.uk/2021/02/04/stroke-victims-to-be-given-psychedelic-drug-dmt-in-groundbreaking-study-14023757/?ito=cbshare
Twitter: https://twitter.com/MetroUK | Facebook: https://www.facebook.com/MetroUK/
Psychedelic drug DMT could help stroke victims recover by rewiring their brains faster, according the first clinical trial of its kind. It is hoped the substance, also known as the ‘the spirit molecule’, could even be given to patients as soon as they’re in the ambulance, minimising the damage and maximising their recovery. Algernon Pharmaceuticals, who set out the plan for their study this week, say participants will be given a microdose, which won’t make them ‘trip’, but will still help the neurons in their brain make new connections. If the trial proves successful and gets regulatory approval, it could open up a whole new world of research for people with multiple sclerosis, Parkinson’s and many other conditions affecting the brain. Among the study’s global luminaries is Professor David Nutt, of Imperial College London’s Centre for Psychedelic Research, which has looked into potential for psilocybin (magic mushrooms) to treat depression. Algernon, based in Vancouver, Canada, are the world’s first company to try using DMT (dimethyltryptamine) for strokes, and if they get promising results, they hope to be fast-tracked by regulators in the US. CEO Christopher Moreau told Metro.co.uk: Since we’re dealing with stroke patients, we will be using the sub-hallucinogenic dose, which in pre-clinical studies has still shown to improve neuroplasticity. ‘It will help the brain heal even though patients aren’t having the psychedelic experience, and we really don’t want that if your patient has just had a stroke.’ DMT occurs in many plants and animals, but Algernon will produce theirs synthetically (Picture: Getty Images) Algernon have been buoyed by a study last year in which blood flow was blocked off for one half of the brain in rats. Rodents who were given DMT recovered motor-function and rebuilt brain cells more efficiently and had fewer lesions on the brain. ‘We’re going to take that information now and move very quickly to test it in humans,’ Mr Moreau said. He explained how there is still ‘very little available’ for stroke victims in the immediate aftermath and that DMT could help fill the void. Part of the problem is that two of the main types of stroke are very different and require different types of treatment. Christopher Moreau, CEO of Algernon Pharmaceuticals, based in Vancouver, Canada Christopher Moreau hopes the study could open a whole new field for people with other illnesses (Picture: Algernon Pharmaceuticals) Ischemic strokes occur due to a blood clot blocking a vessel in the brain and are often treated with blood thinner. But if you did this for someone suffering from a haemorrhagic stroke – caused by bleeding in or around the brain – you could kill them. For this reason patients have to wait for a CT scan, which could take hours, leaving more time for the brain to incur damage. Mr Moreau said: ‘The sooner you can start to treat post-injury the better. DMT may not benefit hemorrhagic, we don’t know, but we’re hoping it won’t cause them any problems because then we don’t have to wait for the CT scan, we can treat in the ambulance.
Read more: https://metro.co.uk/2021/02/04/stroke-victims-to-be-given-psychedelic-drug-dmt-in-groundbreaking-study-14023757/?ito=cbshare
Twitter: https://twitter.com/MetroUK | Facebook: https://www.facebook.com/MetroUK/
Psychedelic drug DMT could help stroke victims recover by rewiring their brains faster, according the first clinical trial of its kind. It is hoped the substance, also known as the ‘the spirit molecule’, could even be given to patients as soon as they’re in the ambulance, minimising the damage and maximising their recovery. Algernon Pharmaceuticals, who set out the plan for their study this week, say participants will be given a microdose, which won’t make them ‘trip’, but will still help the neurons in their brain make new connections. If the trial proves successful and gets regulatory approval, it could open up a whole new world of research for people with multiple sclerosis, Parkinson’s and many other conditions affecting the brain. Among the study’s global luminaries is Professor David Nutt, of Imperial College London’s Centre for Psychedelic Research, which has looked into potential for psilocybin (magic mushrooms) to treat depression. Algernon, based in Vancouver, Canada, are the world’s first company to try using DMT (dimethyltryptamine) for strokes, and if they get promising results, they hope to be fast-tracked by regulators in the US. CEO Christopher Moreau told Metro.co.uk: Since we’re dealing with stroke patients, we will be using the sub-hallucinogenic dose, which in pre-clinical studies has still shown to improve neuroplasticity. ‘It will help the brain heal even though patients aren’t having the psychedelic experience, and we really don’t want that if your patient has just had a stroke.’ DMT occurs in many plants and animals, but Algernon will produce theirs synthetically (Picture: Getty Images) Algernon have been buoyed by a study last year in which blood flow was blocked off for one half of the brain in rats. Rodents who were given DMT recovered motor-function and rebuilt brain cells more efficiently and had fewer lesions on the brain. ‘We’re going to take that information now and move very quickly to test it in humans,’ Mr Moreau said. He explained how there is still ‘very little available’ for stroke victims in the immediate aftermath and that DMT could help fill the void. Part of the problem is that two of the main types of stroke are very different and require different types of treatment. Christopher Moreau, CEO of Algernon Pharmaceuticals, based in Vancouver, Canada Christopher Moreau hopes the study could open a whole new field for people with other illnesses (Picture: Algernon Pharmaceuticals) Ischemic strokes occur due to a blood clot blocking a vessel in the brain and are often treated with blood thinner. But if you did this for someone suffering from a haemorrhagic stroke – caused by bleeding in or around the brain – you could kill them. For this reason patients have to wait for a CT scan, which could take hours, leaving more time for the brain to incur damage. Mr Moreau said: ‘The sooner you can start to treat post-injury the better. DMT may not benefit hemorrhagic, we don’t know, but we’re hoping it won’t cause them any problems because then we don’t have to wait for the CT scan, we can treat in the ambulance.
Read more: https://metro.co.uk/2021/02/04/stroke-victims-to-be-given-psychedelic-drug-dmt-in-groundbreaking-study-14023757/?ito=cbshare
Twitter: https://twitter.com/MetroUK | Facebook: https://www.facebook.com/MetroUK/
